You are here:
INFRAFRONTIER, a leading player in biomedical research infrastructure, headquartered at Helmholtz Munich, was officially declared as a European Research Infrastructure Consortium (ERIC) by the European Commission. This milestone represents a…
Research targeting the insulin-inhibitory receptor, called inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. A novel study in mice with diet-induced obesity demonstrates that the knock-out of…
The genetic information in our cells harbors secrets about the risks, progression, and complications of many diseases. With hundreds of millions of patients worldwide, identifying and understanding genetic risk for type 2 diabetes is of particular…
Dr. Siegfrid Ussar, Head of the new research unit “Adipocytes & Metabolism” at Helmholtz Munich, is researching ways to decouple obesity and its metabolic complications. This is particularly important given the significant health problems caused by…
Sex-Specific Research
A recent discovery led by Helmholtz Munich researchers from the Type 1 Diabetes Immunology Research Unit has uncovered how regulatory immune T-cells (called Tregs) interplay and control metabolic tissues. The new findings published in Cell…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
